• No results found

Vitamin K antagonist

Rivaroxaban and other non-vitamin K antagonist oral anticoagulants in the emergency treatment of thromboembolism

Rivaroxaban and other non-vitamin K antagonist oral anticoagulants in the emergency treatment of thromboembolism

... and vitamin K antagonists, although effective and recommended by guidelines, are associated with ...a vitamin K antagonist for the prevention of recurrent, symptomatic venous ...

9

Portable coagulometer for vitamin K-antagonist monitoring: the patients’ point of view

Portable coagulometer for vitamin K-antagonist monitoring: the patients’ point of view

... Purpose: The aim of this study was to know the patients’ point of view on the monitoring of vitamin K-antagonist (VKA) therapy by means of a point of care testing (POCT), ie, using a portable ...

6

Non-vitamin K antagonist oral anticoagulants vs. vitamin-K antagonists in patients with atrial fibrillation and chronic kidney disease: a nationwide cohort study

Non-vitamin K antagonist oral anticoagulants vs. vitamin-K antagonists in patients with atrial fibrillation and chronic kidney disease: a nationwide cohort study

... Danish study found that AF patients with non-end-stage CKD or end-stage CKD had an increased risk of stroke/ TE of 50 and 83%, respectively, compared to patients without renal disease [2]. Furthermore, the presence of ...

8

Effective management of venous thromboembolism in the community: non-vitamin K antagonist oral anticoagulants

Effective management of venous thromboembolism in the community: non-vitamin K antagonist oral anticoagulants

... pathways for most patients with DVT typically involve initial hospital or community- based ambulatory care with subsequent follow-up in a secondary care setting. An increasing number of patients with low-risk PE are also ...

9

Strengths and weaknesses of ‘real-world’ studies involving non-vitamin K antagonist oral anticoagulants

Strengths and weaknesses of ‘real-world’ studies involving non-vitamin K antagonist oral anticoagulants

... Randomised controlled trials (RCTs) provide the reference standard for comparing the efficacy of one therapy or intervention with another. However, RCTs have restrictive inclusion and exclusion criteria; thus, they are ...

12

Non Vitamin K Antagonist Oral Anticoagulants: Redefining the Role of the Nurse to Improve Patient Care

Non Vitamin K Antagonist Oral Anticoagulants: Redefining the Role of the Nurse to Improve Patient Care

... Non-vitamin K antagonist (VKA) oral anticoagulants (OACs), including rivaroxaban, dabigatran, apixaban and edoxaban, are effective for the preven- tion of stroke in patients with non-valvular atrial ...

16

Practical and clinical considerations in assessing patients with atrial fibrillation for switching to non-vitamin K antagonist oral anticoagulants in primary care

Practical and clinical considerations in assessing patients with atrial fibrillation for switching to non-vitamin K antagonist oral anticoagulants in primary care

... non- vitamin K antagonist oral anticoagulants; RE-LY, the randomized evaluation of long-term anticoagulation therapy; ROCKET-AF, rivaroxaban once daily oral direct factor Xa inhibition compared with ...

9

Anti-inflammatory and antiplatelet effects of non-vitamin K antagonist oral anticoagulants in acute phase of ischemic stroke patients

Anti-inflammatory and antiplatelet effects of non-vitamin K antagonist oral anticoagulants in acute phase of ischemic stroke patients

... non-vitamin K antagonist oral anticoagulants such as direct thrombin and direct factor Xa inhibitors have been prescribed for prevention of embolic ...

6

Stroke prevention in the elderly atrial fibrillation patient with comorbid conditions: focus on non-vitamin K antagonist oral anticoagulants

Stroke prevention in the elderly atrial fibrillation patient with comorbid conditions: focus on non-vitamin K antagonist oral anticoagulants

... non-vitamin K antagonist oral anticoagulants compared with warfarin in the elderly patient population with multiple comorbid conditions are ...

14

Vitamin K antagonist use: evidence of the difficulty of achieving and maintaining target INR range and subsequent consequences

Vitamin K antagonist use: evidence of the difficulty of achieving and maintaining target INR range and subsequent consequences

... ACCP, American College of Chest Physicians; ACTIVE W, Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events; AF, atrial fibrillation; CI, confidence interval; DVT, deep vein thrombosis; ...

10

Prothrombin complex concentrate in surgical patients: retrospective evaluation of vitamin K antagonist reversal and treatment of severe bleeding

Prothrombin complex concentrate in surgical patients: retrospective evaluation of vitamin K antagonist reversal and treatment of severe bleeding

... PCC (about 22 IU/kg) used here in the anticoagulant reversal group (baseline INR 2.8) is comparable with that used by Pab- inger et al. during a recent prospective trial [30], in which 93% of emergency coagulant reversal ...

15

Non-vitamin K antagonist oral anticoagulants in adults with a Fontan circulation: are they safe

Non-vitamin K antagonist oral anticoagulants in adults with a Fontan circulation: are they safe

... Non-vitamin K antagonist oral anticoagulants (NOACs) are an attractive alternative to VKAs with the potential for reduced intracerebral haemorrhage, relatively few dietary or drug interactions and no ...

5

Vitamin K antagonist use and renal function in pre-dialysis patients

Vitamin K antagonist use and renal function in pre-dialysis patients

... of vitamin K antago- nist use on kidney function decline and start of dialysis is probably ...withholding vitamin K antagonists to slow kidney function decline or postpone ...of vitamin ...

8

Implementation of non-vitamin K antagonist oral anticoagulants in daily practice: the need for comprehensive education for professionals and patients

Implementation of non-vitamin K antagonist oral anticoagulants in daily practice: the need for comprehensive education for professionals and patients

... Non-vitamin K antagonist oral anticoagulants (NOACs) are increasingly used for the prevention and treatment of venous thromboembolism and for stroke prevention in patients with atrial ...a ...

14

Efficacy and safety of non-vitamin K antagonist oral anticoagulants compared with warfarin in patients with atrial fibrillation

Efficacy and safety of non-vitamin K antagonist oral anticoagulants compared with warfarin in patients with atrial fibrillation

... Figure 1 Efficacy and safety outcomes with NOAC compared with warfarin in 18638 NOAC patients with 14 457 years of risk and 49 418 warfarin patients with 75 747 person-years at risk. Multivariable Fine-Gray competing ...

9

The Results of Using Electronic Health Software for
Self-Management of Vitamin K Antagonist Therapy: A
Systematic Review

The Results of Using Electronic Health Software for Self-Management of Vitamin K Antagonist Therapy: A Systematic Review

... Introduction and Aim: Currently, between one to two percent of the population of high- income countries is being treated with oral anticoagulants. This trend will continue to increase due to the sedentary lifestyle and ...

8

Updates in the perioperative and emergency management of non vitamin K antagonist oral anticoagulants

Updates in the perioperative and emergency management of non vitamin K antagonist oral anticoagulants

... Perioperative management of patients treated with the non-vitamin K antagonist oral anticoagulants is an ongoing challenge. Due to the lack of good clinical studies involving adequate monitoring and ...

6

Quality of vitamin K antagonist control and outcomes in atrial fibrillation patients: a meta-analysis and meta-regression

Quality of vitamin K antagonist control and outcomes in atrial fibrillation patients: a meta-analysis and meta-regression

... Dickstein K, Lekakis J, McGregor K, Metra M, Morais J, Osterspey A, Tamargo JL, Zamorano JL: ACC/AHA/ESC 2006 guidelines for the management of patients with atrial ...

20

Rivaroxaban versus enoxaparin/vitamin K antagonist therapy in patients with venous thromboembolism and renal impairment

Rivaroxaban versus enoxaparin/vitamin K antagonist therapy in patients with venous thromboembolism and renal impairment

... Anticoagulant treatment is associated with an increased risk of bleeding. Because rivaroxaban is partly excreted renally, a dose reduction in patients with renal impairment would seem plausible. However, severe renal ...

8

Label Adherence for Non Vitamin K Antagonist Oral Anticoagulants in a Prospective Cohort of Asian Patients with Atrial Fibrillation

Label Adherence for Non Vitamin K Antagonist Oral Anticoagulants in a Prospective Cohort of Asian Patients with Atrial Fibrillation

... INTRODUCTION Adjusted doses of warfarin can be prescribed according to prothrombin time in order to achieve a target therapeutic window, which necessitates frequent monitoring.1 In compa[r] ...

8

Show all 10000 documents...

Related subjects